Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Current race in the development of DAAs (direct-acting antivirals) against HCV — De Clercq Erik (2014) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Current race in the development of DAAs (direct-acting antivirals) against HCV
Shared by
De Clercq Erik
KU Leuven
Current race in the development of DAAs (direct-acting antivirals) against HCV
Article
2014
en
Related publications
Article
2017
Current therapy for chronic hepatitis C: The role of direct-acting antivirals
Guangdi Li
,
De Clercq Erik
Article
2016
Effect of HCV clearance with direct-acting antiviral agents on HCC
Josep M. Llovet
,
Augusto Villanueva
Nature Reviews Gastroenterology & Hepatology
Authors
De Clercq Erik
KU Leuven
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Article
2008
Development of a model for the study of antivirals against Molluscum contagiosum
Graciela Andreï
,
Joost van den Oord
,
Rita De Vos
,
Sophie Duraffour
,
A. Blondeel
,
Thierry Simonart
,
De Clercq Erik
,
Robert Snoeck
Article
2008
Antivirals: Current State of the Art
De Clercq Erik
Article
2017
Unique Characteristics Associated with Sustained Liver Damage in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals
Masashi Kono
,
Naoshi Nishida
,
Satoru Hagiwara
,
Tomohiro Minami
,
Hirokazu Chishina
,
Tadaaki Arizumi
,
Kosuke Minaga
,
Ken Kamata
,
Yoriaki Komeda
,
Toshiharu Sakurai
,
Mamoru Takenaka
,
Masahiro Takita
,
Norihisa Yada
,
Hiroshi Ida
,
Yasunori Minami
,
Kazuomi Ueshima
,
Tomohiro Watanabe
,
Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.